Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.0K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

31
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
31
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

36
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
36
Chemical Synapses01:26

Chemical Synapses

9.0K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.0K
Muscle Contraction01:10

Muscle Contraction

6.7K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Unusual Presentation of Dermatomyositis With Muscle Hypertrophy.

Cureus·2023
Same author

Port-Wine Stain and Monomelic Weakness Associated With Perineurioma: A Neuromuscular Image.

Journal of clinical neuromuscular disease·2022
Same author

New patient access via telehealth in neuromuscular medicine during COVID-19.

Work (Reading, Mass.)·2021
Same author

Guidelines on clinical presentation and management of nondystrophic myotonias.

Muscle & nerve·2020
Same author

Skeletal Muscle Channelopathies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2018
Same author

Hereditary and acquired polyneuropathy conditions of the peripheral nerves: clinical considerations and MR neurography imaging.

Seminars in musculoskeletal radiology·2015
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: Aug 16, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.4K

Muscle Channelopathies.

Jaya R Trivedi

    Continuum (Minneapolis, Minn.)
    |December 20, 2022
    PubMed
    Summary
    This summary is machine-generated.

    This review covers nondystrophic myotonia and periodic paralysis, focusing on diagnosis, pathophysiology, and management. Advances in genetic testing and clinical trials offer expanded treatment options for these rare skeletal muscle channelopathies.

    More Related Videos

    Functional Characterization of Endogenously Expressed Human RYR1 Variants
    07:59

    Functional Characterization of Endogenously Expressed Human RYR1 Variants

    Published on: June 9, 2021

    2.6K
    Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
    09:39

    Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

    Published on: July 29, 2016

    15.5K

    Related Experiment Videos

    Last Updated: Aug 16, 2025

    Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
    03:45

    Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

    Published on: August 8, 2022

    3.4K
    Functional Characterization of Endogenously Expressed Human RYR1 Variants
    07:59

    Functional Characterization of Endogenously Expressed Human RYR1 Variants

    Published on: June 9, 2021

    2.6K
    Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
    09:39

    Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

    Published on: July 29, 2016

    15.5K

    Area of Science:

    • Neurology
    • Genetics
    • Molecular Biology

    Background:

    • Skeletal muscle channelopathies, including nondystrophic myotonias and periodic paralyses, are rare, lifelong disorders.
    • Growing understanding of genotype-phenotype correlations necessitates genetic testing for accurate diagnosis.
    • These conditions present diagnostic challenges due to overlapping electrodiagnostic features across mutation subtypes.

    Approach:

    • This review synthesizes current knowledge on the clinical features, diagnosis, pathophysiology, and management strategies.
    • It highlights recent findings from randomized clinical trials, indicating progress in treatment options.
    • The article discusses the complexities of developing treatment trials for rare diseases with variable biophysical characteristics.

    Key Points:

    • Definitive diagnosis of skeletal muscle channelopathies relies on genetic testing due to genotype-phenotype overlap.
    • Electrodiagnostic testing is specialized and shows significant overlap among different mutation subtypes.
    • Recent clinical trials have expanded the therapeutic landscape for these channelopathies.

    Conclusions:

    • Skeletal muscle channelopathies require comprehensive, lifelong management involving pharmacologic and nonpharmacologic interventions.
    • The heterogeneity of mutations and rarity of these diseases pose challenges for clinical trial design and implementation.
    • Despite challenges, advancements in genetic testing and clinical research are improving patient care and treatment options.